Sort   by:  
 Page size 
ProteomicsIntegrative functional proteomics identifies PARP1 protein complex differences and PARP inhibitor-mediated DDR and AKT-mTOR signaling in ovarian carcinoma: Phosphoproteomics
BRCA1/2-deficient ovarian carcinoma (OC) has been shown to be particularly sensitive to PARP inhibitors (PARPis) and BRCA1/2 mutation status is currently used as a predictive biomarker for PARPi therapy. Despite eliciting major clinical benefit for the majority of patients, a significant proportion ...
ORGANISM(S): Homo sapiens (Human) 
2022-10-21 | PXD029432 | Pride
Ovarian cancer Phosphoproteomics Parp1 Brca 
UnknownRemote mental health services: a mixed-methods survey and interview study on the use, value, benefits and challenges of a national video consulting service in NHS Wales, UK.
Not available
S-EPMC8487209 | biostudies-literature
UnknownImproving Mental Health Through the Regeneration of Deprived Neighborhoods: A Natural Experiment.
Not available
S-EPMC5860549 | biostudies-literature
UnknownRecombinant inbred lines derived from wide crosses in Pisum.
Not available
S-EPMC10663473 | biostudies-literature
UnknownReduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study.
Not available
S-EPMC8126150 | biostudies-literature
UnknownPhase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Not available
S-EPMC3577951 | biostudies-literature
UnknownReal-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Not available
S-EPMC9911979 | biostudies-literature
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Phosphoproteomics
PARP1 inhibitors (PARP1is ) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, ...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020484 | Pride
Adavosertib Phosphoproteomics Parp16 Lung cancer Parp1 Polypharmacology Parp inhibitor Ewing’s sarcoma Off-target Talazoparib 
UnknownClinical outcomes following acute sore throat assessment at community pharmacy versus general practice: a retrospective, longitudinal, data linkage study.
Not available
S-EPMC11695917 | biostudies-literature
UnknownAlcohol's harms to others in Wales, United Kingdom: Nature, magnitude and associations with mental well-being.
Not available
S-EPMC6542752 | biostudies-literature
Sort   by:  
 Page size